Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Helicase inhibitors act on the enzymes that unwind DNA and RNA duplexes during replication and repair. Helicases use adenosine triphosphate (ATP) to separate nucleic acid strands, which gives repair and recombination machinery access to single strands. Cancer cells with microsatellite instability were found in 2019 to depend on the Werner syndrome helicase (WRN), and expanded thymine-adenine (TA) dinucleotide repeats were later linked to that dependence. The list reflects this focus with WRN inhibitors such as VVD-214 and NSC 617145. Related RecQ family enzymes are covered by BLM-IN-2 against the Bloom syndrome helicase (BLM) and by RECQL5-IN-1. DHX9-IN-1 acts on the RNA helicase DExH-box helicase 9 (DHX9), which resolves R-loops and other structured nucleic acids.
DHX9-IN-4 is an ATP-dependent inhibitor of the RNA helicase A (DHX9). This compound demonstrates significant inhibitory activity against DHX9, making it a valuable tool in cancer research. Its mechanism of action may provide insights into the role of RNA helicases in tumor biology and therapeutic approaches.
WRN Inhibitor 11 is a potent orally active inhibitor of the WRN helicase, exhibiting an IC50 value of 63 nM. This compound disrupts the helicase activity of WRN, a critical enzyme involved in DNA repair and maintenance of genomic stability. WRN Inhibitor 11 is valuable for research applications in cancer biology and studies involving disorders linked to defective DNA repair mechanisms.
Out of stock
All 3 sizes
WRN Inhibitor 17 is a potent inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN), specifically targeting its helicase domain activity. This small molecule demonstrates significant potential in research applications related to cancer, offering insights into the role of WRN in tumor biology and therapeutic strategies. Its ability to modulate WRN function makes it a valuable tool for studying DNA damage response and repair mechanisms in cancer cells.
Out of stock
All 3 sizes
DHX9-IN-8 is a specific inhibitor of the RNA helicase DHX9, exhibiting an EC50 value of 3.4 μM in cellular assays. This compound is utilized in cancer research to investigate the role of DHX9 in tumorigenesis and related pathways. Its application in molecular biology studies contributes to the understanding of RNA processing and regulation in various cancer types.
DHX9-IN-14 is a specific inhibitor of the RNA helicase DHX9, demonstrating an effective EC50 value of 3.4 μM for cellular target engagement. This compound plays a critical role in cancer research, where modulation of DHX9 activity has potential therapeutic implications. It is valuable for investigating the involvement of DHX9 in various oncogenic processes and biological pathways.
DHX9-IN-15 is a selective inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.232 μM in cellular assays. This compound significantly disrupts DHX9 activity, making it a valuable tool for investigating its role in oncology and cancer-related pathways. Its unique mechanism positions it as an important reagent for research into cancer therapeutics and RNA biology.
Out of stock
All 3 sizes
DHX9-IN-19 is a potent inhibitor of the RNA helicase DHX9, which plays a crucial role in RNA metabolism and cancer progression. This compound demonstrates significant biological activity in disrupting DHX9 function, making it a valuable tool in cancer research. Researchers can utilize DHX9-IN-19 to explore the role of DHX9 in various malignancies and to develop targeted therapeutic strategies.
Out of stock
All 3 sizes
DHX9-IN-12 is an inhibitor targeting the RNA helicase DHX9, exhibiting an EC50 of 0.917 μM for cellular target engagement. This compound is primarily utilized in cancer research to investigate the regulatory roles of DHX9 in tumor biology and RNA metabolism. Its application aids in the understanding of molecular mechanisms underlying various cancer types, facilitating the development of potential therapeutic strategies.
DHX9-IN-16 is a selective inhibitor of the RNA helicase DHX9, demonstrating an EC50 value of 0.125 μM in cellular target engagement. This compound is employed in cancer research to investigate the role of DHX9 in various neoplastic processes and cellular functions. Its ability to modulate RNA helicase activity makes it a valuable tool for studying mRNA metabolism and potential therapeutic pathways in oncology.
Out of stock
All 3 sizes
DHX9-IN-7 is a selective inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 0.105 μM in cellular target engagement. This compound is essential for studies investigating the role of DHX9 in various cancer biological processes. Its inhibitory activity provides a valuable tool for elucidating the molecular mechanisms underlying cancer progression and potential therapeutic interventions.
Out of stock
All 3 sizes
WRN Inhibitor 13 is a selective inhibitor of the WRN helicase, exhibiting a pIC50 value in the range of 6-7. This compound is valuable for studies focused on DNA repair mechanisms, particularly in relation to cancer research and aging. WRN Inhibitor 13 aids in elucidating the role of WRN helicase in maintaining genomic stability and offers potential therapeutic avenues for WRN-related diseases.
Out of stock
All 3 sizes
DHX9-IN-13 is a selective inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 3.4 μM in cellular assays. This compound is primarily utilized in cancer research to elucidate the role of DHX9 in tumorigenesis and associated signaling pathways. Its mechanism of action allows for the investigation of RNA metabolism and the potential therapeutic targeting of DHX9 in cancer treatment strategies.
Out of stock
All 3 sizes
WRN Inhibitor 12 is a selective inhibitor of the Werner syndrome protein (WRN) helicase. This compound effectively modulates WRN's helicase activity, which plays a crucial role in DNA repair and maintenance. WRN Inhibitor 12 is valuable for research applications focused on aging, genomic instability, and the study of chromosomal dynamics.
Out of stock
All 3 sizes
WRN-IN-24 is an orally active allosteric covalent inhibitor of Werner syndrome helicase (WRN), exhibiting an IC50 of 201 nM. By binding to a unique allosteric pocket and forming a hydrogen bond with K894, WRN-IN-24 effectively inhibits WRN activity. This compound demonstrates significant antiproliferative effects on colorectal cancer cells and shows dose-dependent antitumor efficacy in xenograft mouse models. WRN-IN-24 is a valuable tool for investigating microsatellite instability-high cancers, particularly in colorectal cancer research.
Out of stock
All 3 sizes
WRN Inhibitor 7 is a selective inhibitor targeting the Werner helicase (WRN). It effectively inhibits both the helicase and ATPase activities of WRN, with IC50 values of 9.8 μM and 15.8 μM, respectively. This compound is valuable for research focused on microsatellite unstable (MSI) cancers, providing a tool for investigating the role of WRN in DNA repair and tumorigenesis.
Out of stock
All 3 sizes
KWR095 is a potent WRN inhibitor that targets the WRN ATPase with an IC50 value of 0.032 μM. By obstructing the duplex unwinding activity of WRN, KWR095 effectively inhibits the proliferation of tumor cells, demonstrating significant anti-tumor activity. This compound is valuable for research applications focused on cancer biology and the mechanisms of DNA repair.
Out of stock
All 3 sizes
WRN-IN-19 is a covalent inhibitor of the WRN helicase, demonstrating a pIC50 of 5.4 at 0 hours and 7.5 at 4 hours in DNA unwinding assays. This compound exhibits synthetic lethality in high microsatellite instability (MSI-H) cancer cells, making it a valuable tool for studying the mechanisms of DNA repair and potential therapeutic strategies in cancer research. Its targeted action on WRN helicase positions it as a critical reagent for investigations into the role of helicases in cancer biology.
Out of stock
All 3 sizes
WRN Inhibitor 18 is a selective inhibitor of Werner syndrome protein (WRN) that disrupts its helicase activity, leading to impaired DNA repair processes. This compound exhibits in vivo anticancer activity, making it a valuable tool for research into cancer therapeutics and the mechanisms underlying genomic instability. Its application extends to studying the role of WRN in cellular processes, including replication stress and tumor progression.
Out of stock
All 3 sizes
DHX9-IN-11 is a selective inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 0.0838 μM in cellular assays. This compound is primarily utilized in cancer research, facilitating investigations into the role of DHX9 in tumorigenesis and its potential as a therapeutic target. Its activity provides a valuable tool for elucidating the molecular mechanisms involving RNA processing and regulation in cancer cells.
Out of stock
All 3 sizes
DHX9-IN-10 is a selective inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 9.04 μM in cellular target engagement studies. This compound is valuable for investigating the role of DHX9 in cancer biology and can be utilized in research settings focused on RNA metabolism and therapeutic development. Its inhibition of DHX9 provides insights into mechanisms of oncogenesis and potential therapeutic strategies.
DHX9-IN-17 is a selective inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 0.161 μM in cellular target engagement. This compound is instrumental in cancer research, enabling the investigation of DHX9's role in RNA metabolism and its implications in tumorigenesis. By modulating DHX9 activity, DHX9-IN-17 serves as a valuable tool for studying cancer biology and the development of potential therapeutic strategies.
Out of stock
All 3 sizes
DHX9-IN-18 is a selective inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 16.4 μM. This compound demonstrates significant biochemical activity, with an infection point of 0.32 μM. DHX9-IN-18 is suitable for research applications focusing on cancer biology and the role of RNA helicases in tumor progression.
WRN-IN-23 is a selective inhibitor of the Werner Syndrome helicase (WRN), targeting its ATP-dependent helicase domain activity. This compound effectively interferes with DNA unwinding processes, making it a valuable tool for investigating cancers associated with microsatellite instability (MSI) and defective DNA mismatch repair (dMMR) mechanisms. WRN-IN-23's ability to modulate WRN activity provides insights into the roles of helicases in cancer biology and may contribute to the development of therapeutic strategies for these tumor types.
Out of stock
All 3 sizes
DDX3-IN-2 is a potent inhibitor of DEADbox polypeptide 3 (DDX3) with an IC50 value of 0.3 μM. It demonstrates a broad range of antiviral activity, making it a valuable tool in the study of viral infections. Additionally, DDX3-IN-2 may serve as a potential therapeutic agent to combat HIV resistance, aiding research into innovative treatment strategies.
ABI-5366 is an inhibitor of helicase-primase, targeting viral replication mechanisms. This compound demonstrates significant efficacy against herpes simplex virus (HSV) infection, making it a valuable tool for research in antiviral therapies and the molecular biology of HSV. Its ability to interfere with the helicase-primase complex highlights its potential in developing novel antiviral strategies.
